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Abstract
Exposure to monomethylarsonic acid (MMA(V)) and monomethylarsonous acid (MMA(III)) can
result from their formation as metabolites of inorganic arsenic and by the use of the sodium salts of
MMA(V) as herbicides. This study compared the disposition of MMA(V) and MMA(III) in adult
female B6C3F1 mice. Mice were gavaged po with MMA(V), either unlabeled or labeled with 14C
at two dose levels (0.4 or 40 mg As/kg). Other mice were dosed po with unlabeled MMA(III) at one
dose level (0.4 mg As/kg). Mice were housed in metabolism cages for collection of excreta and
sacrificed serially over 24 h for collection of tissues. MMA(V)-derived radioactivity was rapidly
absorbed, distributed and excreted. By 8 h post-exposure, 80% of both doses of MMA(V) were
eliminated in urine and feces. Absorption of MMA(V) was dose dependent; that is, there was less
than a 100-fold difference between the two dose levels in the area under the curves for the
concentration-time profiles of arsenic in blood and major organs. In addition, urinary excretion of
MMA(V)-derived radioactivity in the low dose group was significantly greater (P < 0.05) than in the
high dose group. Conversely, fecal excretion of MMA(V)-derived radioactivity was significantly
greater (P < 0.05) in the high dose group than in the low dose group. Speciation of arsenic by hydride
generation-atomic absorption spectrometry in urine and tissues of mice administered MMA(V) or
MMA(III) found that methylation of MMA(V) was limited while the methylation of MMA(III) was
extensive. Less than 10% of the dose excreted in urine of MMA(V)-treated mice was in the form of
methylated products, whereas it was greater than 90% for MMA(III)-treated mice. In MMA(V)-
treated mice, 25% or less of the tissue arsenic was in the form of dimethylarsenic, whereas in MMA
(III)-treated mice, 75% or more of the tissue arsenic was in the form of dimethylarsenic. Based on
urinary analysis, administered dose of MMA(V) did not affect the level of its metabolites excreted.
In the tested range, dose affects the absorption, distribution and route of excretion of MMA(V) but
not its metabolism.
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The metalloid arsenic occurs in a variety of inorganic and organic forms. The multiplicity of
arsenicals, each with unique chemical and toxicological activities, complicates the risk
management for human exposure to this diverse group of compounds. Monomethylarsonic
acid (MMA(V)), an organic arsenical in the pentavalent oxidation state, is of public health
significance because its mono- and disodium salt forms are registered herbicides in the United
States. In addition, MMA(V) is a methylated metabolite found in the urine of humans exposed
to inorganic arsenic (iAs) (Aposhian et al., 2000; Del Razo et al., 2001; Mandal et al., 2001).
Hence, exposure to MMA(V) can occur externally by its use as a pesticide and internally from
the metabolism of iAs.
MMA(V) administered po is well absorbed by several species, including humans. Based on
urinary excretion data, 75% or more of a dose of MMA(V) administered po was absorbed by
goats (10 mg As/kg ), sheep (10 mg As/kg) (Shariatpanahi and Anderson, 1984) and humans
(500 μg As) (Buchet et al., 1981). The absorbed dose was excreted in urine fairly rapidly by
these species. By comparison, hamsters appear to absorb less MMA(V) than other species. By
24 h post-dosing, 56% of a po dose (27 mg As/kg) of MMA(V) was eliminated in feces
(Yamauchi et al., 1988). In contrast, biliary excretion of MMA(V) administered ip (27 mg As/
kg) to hamsters was minimal, as 78% of the administered dose was excreted in urine by 24 h
(Yamauchi et al., 1988).
MMA(V) is not extensively metabolized by mammals to methylated products. Less than 10%
of a po administered dose of MMA(V) to humans (500 μg As) (Buchet et al., 1981) or hamsters
(3–166 mg As/kg) (Yamauchi et al., 1988) or iv to mice (0.4 or 40 mg As/kg) (Hughes and
Kenyon, 1998) or rats (0.2–0.25 mg/kg) (Cui et al., 2004; Suzuki et al., 2004a) was converted
to dimethylarsenic species. In vitro studies with rat liver cytosol (Styblo et al., 1995), rat and
human hepatocytes (Styblo et al., 1999) or human recombinant arsenic methyltransferase
(Hayakawa et al., in press) also show that methylation of MMA(V) was minimal. In contrast,
monomethylarsonous acid (MMA(III)) (trivalent monomethylarsenic) was readily methylated
in vitro to dimethylarsenic (Styblo et al., 1995, 1999). Recent studies with trivalent
monomethylarsenic, formed by reacting MMA(V) with thiols, and administered po (0.1–0.5
mg/ kg) (Cui et al., 2004) or iv (0.5 mg/kg) (Suzuki et al., 2004b) to rats showed that it was
methylated to DMA(V). The low rate of conversion of MMA(V) is surprising, given the relative
rapidity of iAs methylation by many species. Based on a proposal by Challenger (1945),
metabolism of arsenic involves sequential reduction and oxidative methylation. MMA(V) is
an intermediary in this pathway to the primary arsenical metabolite, dimethylarsinic acid
(DMA(V)). However, Hayakawa et al. (in press) recently proposed that MMA(V) is not an
intermediary of iAs methylation, but a product of the intermediate monomethylarsenic
diglutathione. Regardless of the pathway of iAs metabolism, both MMA(V) and MMA(III)
are excreted in the urine of individuals that consume drinking water contaminated with iAs
(Aposhian et al., 2000; Del Razo et al., 2001; Le et al., 2000; Mandal et al., 2001).
MMA(V) is relatively non-toxic after acute exposure. The oral LD50s of MMA(V) and its
sodium salts are 1.8 g/ kg in mice (Kaise et al., 1989) and >800 mg/kg (Gaines and Linder,
1986) in rats. The reproductive capacity of male mice repeatedly administered the monosodium
salt of MMA(V) (MSMA) (11.9 and 119 mg/kg) over several weeks was reduced (Prukop and
Savage, 1986). Hepatic inflammation was observed in rabbits after dietary exposure to MSMA
(50 ppm) for 7 or 12 weeks (Exon and Harr, 1974). MMA(V) does not appear to be a carcinogen.
In a 2-year MMA(V) dietary study, tumors were not observed in mice (10–400 ppm) or rats
(50–130 ppm) (Arnold et al., 2003). The large intestine was the primary target organ of MMA
(V)-induced toxicity for both species, producing non-tumorigenic lesions in the rectum, colon
and cecum.
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In contrast to MMA(V), MMA(III) is a potent acute toxicant. In hamsters, the LD50 of MMA
(III) after ip administration (29.3 μmol/kg) was 3–4 times lower than the LD50 of arsenite (112
μmol/kg) (Petrick et al., 2001). MMA(III) was a more potent cytotoxicant than arsenite in
human Chang liver cells (Petrick et al., 2000), human hepatocytes (Styblo et al., 2000) and
several other human and rodent cell types (Styblo et al., 2000). MMA(III) was a direct-acting
genotoxin, whereas MMA(V) was not active (Andrewes et al., 2003; Kligerman et al., 2003;
Mass et al., 2001). The chronic effects of exposure to MMA(III) are not known. Because of
the differences in toxicity between MMA(V) and MMA(III), the hypothesis that methylation
of iAs is a detoxication mechanism has been questioned. The formation of methylated
metabolites of iAs that retain trivalent arsenic is a mechanism for the activation of arsenic to
reactive and toxic species.
This study examined the effect of dose on the tissue dosimetry, metabolism and excretion of
MMA(V) after po administration to female B6C3F mice. These results were also compared to
those of a single dose of MMA(III).
Methods
Chemicals
[14C]-Disodium monomethylarsonate (specific activity, 10 mCi/mmol) was obtained from ICN
Radiochemicals (Irvine, CA, USA). The radiochemical purity of the compound, determined
by ion chromatography/radio-flow detection (Hughes and Thompson, 1996), was greater than
98%. DMA(V) was purchased from Ansul (Weslaco, TX, USA). Sodium arsenate and sodium
arsenite were obtained from Sigma (St. Louis, MO, USA). The disodium salt of MMA(V)
(purity, 99%) was purchased from AccuStandard (New Haven, CT, USA). Monomethylarsine
oxide (MMA(III)) (purity, 98%) and dimethylarsine iodide (DMA(III)) (purity, 98%) were
synthesized by Dr. William Cullen (University of British Columbia, Vancouver, British
Columbia, Canada). Carbo-sorb E, Permafluor E and Ultima Gold were obtained from Perkin
Elmer (Meriden, CT, USA). Sodium borohydride, sodium hydroxide and ACS certified nitric,
sulfuric, perchloric and hydrochloric acids used in the total arsenic analysis were purchased
from EM Science (Gibbstown, NJ, USA). Antifoam B silicone emulsion and phosphoric acid
(Ultrapure) were from Mallinckrodt Baker, Inc. (Phillipsburg, NJ, USA). Freeze-dried urine
standard reference materials for toxic metals (SRM 2670, National Institute of Standards and
Technology, Gaithersburg, MD, USA) containing a low (60 ng/ml) and high level (480 ng/ml)
of arsenic were used for total arsenic analysis. All other chemicals used were of the highest
grade commercially available.
Animals
Female B6C3F1 mice were from Charles River Laboratories (Raleigh, NC, USA). Mice were
housed in a facility approved by the American Association for Accreditation of Laboratory
Animal Care and maintained in accordance with the Guide on the Care and Use of Laboratory
Animals. Mice were initially group housed in polycarbonate cages with bedding of pine
shavings and were provided Prolab RMH300 (Purina, St. Louis, MO, USA) (containing <1
ppm arsenic) and tap water ad libitum throughout the experiment. Mice were transferred to
metabolism cages (Nalge Co., Rochester, NY, USA) 5 days before dosing. The animal room
was on a 12:12-h light/dark cycle, the temperature was 22 ± 1 °C and humidity was 50 ± 10%.
The average weight of the treated mice was 25 gm and their age ranged from 90 to 120 days.
Experimental
The [14C]-MMA(V) dosing solution was prepared in HPLC-grade water (Burdick and Jackson,
Muskegon, MI, USA) and administered by po gavage (10 ml/kg) at a dose level of 0.4 or 40
mg of elemental As per kg body weight. These doses correspond to 4.8 and 480 μmol/kg of
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MMA(V) (disodium salt) (1.4 and 140 mg/kg), respectively. Each animal was administered
approximately 1.2 μCi of radioactivity. Mice were housed individually in metabolism cages
after dosing. Mice were sacrificed by exsanguination (cardiac puncture) under CO2-induced
anesthesia at 0.25, 0.5, 1, 2, 4, 8, 12 or 24 h post-dosing. Unless otherwise indicated, there
were four mice/time point. Kidney, liver, lung and urinary bladder were removed from the
mice. Tissues were weighed, frozen in liquid nitrogen and stored at −70 °C until processed for
analysis of radioactivity. Processed samples were combusted in a Perkin Elmer model D307
oxidizer. Radioactivity was analyzed in a Perkin Elmer 2560 liquid scintillation counter. Urine
and feces were collected at the time of sacrifice. Each metabolism cage was washed with 75
ml of diluted Count-Off (DuPont, Boston, MA, USA). The cage wash was collected and diluted
to 100 ml with distilled water. Aliquots of urine and cage wash were mixed with scintillant
and assayed for radioactivity. The urine and cage wash radioactivity data were combined. Feces
were weighed and combusted before analysis for radioactivity.
In metabolism studies, mice were housed individually in metabolism cages and administered
po unlabeled MMA(III) (0.4 mg As/kg, 0.56 mg MMA(III)/kg) or MMA(V) (0.4 or 40 mg As/
kg). Control mice were administered water. Urine was collected for 24 h on dry ice. Mice were
sacrificed as described above and tissues (urinary bladder, kidney, liver and lung) were
removed. Urine of control and MMA(III)-treated mice was analyzed for speciated arsenicals
(see below) on the day of collection, while urine of MMA(V)-treated mice was stored at −70
°C until similarly analyzed. Total arsenic was determined in urine collected from all treatment
groups that was stored at −70 °C. A second group of mice were sacrificed 2 h after
administration of MMA(III) or MMA(V). Tissues were removed, weighed, frozen in liquid
nitrogen and stored at −70 °C until analyzed for arsenicals as described below. Results from
the tissue time course study indicated that the peak tissue concentration of MMA(V)-derived
radioactivity was between 0.25 and 4 h. Therefore, the 2-h time point was chosen to collect
and analyze tissues for speciated and total arsenic.
Speciation of aliquots of cumulative 24-h urinary arsenic was done by pH selective hydride
generation (HG)-atomic absorption spectrometry (AAS) as described by Devesa et al.
(2004). This method used a Perkin-Elmer model 5400 atomic absorption spectrometer (Perkin-
Elmer, Norwalk, CT, USA) coupled with a manual hydride generation system at pH 1 or pH
6 and a glass U-tube packed with Chromosorb WAW-dimethyldichlorosilane 46/60 (Supelco,
Inc., Bellefonte, PA) immersed in a liquid nitrogen cold trap. With this methodology, arsines
from trivalent arsenicals and trimethylarsine oxide (TMAO) are selectively generated at pH 6,
cold-trapped and separated by their boiling points. At pH 1, arsines are generated from both
tri- and pentavalent arsenicals. Detection limits ranged from 0.15 ng for TMAO to 0.4 ng for
iAs (Devesa et al., 2004).
Tissue samples were digested before HG-AAS analysis. Liver, kidney and lung samples were
homogenized in deionized water (100 mg tissue/ml water). Urinary bladder was digested
without homogenization. Samples were digested in 3 ml of 2 M ultrapure phosphoric acid at
90 °C overnight. For low dose samples, 0.25 ml of homogenate (25 mg of tissue) was digested.
For high dose samples, 0.1 ml of homogenate (10 mg of tissue) was digested. For blood, 0.25
ml aliquots were digested. Tissue samples were analyzed by the method as described above
for urine. However, the analysis was carried out only at pH 1 because complete oxidation of
trivalent arsenicals to pentavalency occurs during digestion. Thus, the oxidation state of
monomethyl (MMA)- and dimethylarsenic (DMA) detected in tissues cannot be distinguished
by this method. Stability of the arsenicals during digestion was tested by incubating aqueous
standards in phosphoric acid overnight at 90 °C. Recoveries of speciated arsenicals were tested
by analysis of total arsenic contents by HG-atomic fluorescence spectrometry (AFS) as
described below.
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Identification and quantification of arsenic in urine and tissues were performed by spiking
samples with standards at different concentrations. Calibration curves for 0.5, 2.5, 10, 20 and
80 ng As for each standard (pH 1, sodium arsenate, MMA(V), DMA(V); pH 6, sodium arsenite,
MMA(III), DMA(III), TMAO) were generated to quantify results for the speciation analyses
at both pH 1 and 6. Stock solutions of 100 ng/ml of As were used for calibration. The peak
area was used to quantify determinations made in urine and tissues. It should be noted that no
standard reference material certified for analysis of mono-, di- and trimethylated arsenicals is
currently available. Therefore, sample aliquots spiked with authentic As standards were used
for quality control during the speciation analysis of As.
Total arsenic in mouse urine and tissues was analyzed by HG-AFS using an automated ProStar
410 autosampler and 9012 quaternary pump (Varian Analytical Instruments, Palo Alto, CA,
USA) with a Millennium Excalibur HG-AFS system (PS Analytical Ltd., Kent, England).
Urine and tissues were completely wet-digested by sequential addition of nitric, sulfuric and
perchloric acids as described by Cox (1980) and modified by Devesa et al. (2004). This
digestion converts all arsenicals to iAs for HG-AFS determination. The instrumental limit of
detection was 0.15 ng As. Recovery of arsenic from urine and tissues was calculated by
comparing the sum of the concentrations of arsenic species detected by HG-AAS with total
arsenic concentration values determined by HG-AFS (((Σ[arsenic species])/[total arsenic])
×100).
Data are listed throughout the text as mean ± SD. SAS System for Windows (Version 8.2;
Cary, NC, USA) was used to analyze the data. Urinary and fecal excretion data were analyzed
by PROC GLM with repeated measures and classifications of dose and time. Significant dose
effects were further tested at each time point using Fisher’s least significant-difference test.
Tissue data were analyzed by PROC GLM and classifications of dose and time. Significant
dose effects were further tested at each time point by Fisher’s least significant-difference test.
Effects were considered statistically significant at P < 0.05. PK Solutions Version 2.06
(Summit Research Services, Montrose, CO, USA) was used to determine the area under the
curve (AUC) for the arsenic tissue concentration-time profiles. The relative bioavailability
(F) for each dose of administered MMA(V) was determined by the following equation: F =
(Xpo/Xiv), where X represents the 24-h cumulative amount of MMA(V)-derived radioactivity
excreted in urine after po or iv administration. The iv data were from Hughes and Kenyon
(1998). Clearance (CL) of MMA(V)-derived radioactivity from the blood was determined by
the following equation: CL = (dose * F)/AUCblood.
Results
MMA(V) was rapidly absorbed and distributed throughout the mouse after po administration;
MMA(V)-derived radioactivity was detected at the earliest time point, 0.25 h post-dosing, in
blood and all organs examined. Peak tissue concentrations of MMA(V)-derived radioactivity,
based on % dose/g, occurred between 0.25 and 4 h post-administration for both dose groups
(Fig. 1). Peak concentrations of MMA(V)-derived radioactivity were greater in bladder, kidney
and lung than in blood, suggesting uptake of arsenic by these tissues. Urinary bladder from 0.4
mg As/ kg MMA(V)-dosed mice, 4 h post-exposure, had the highest concentration (1.47 ±
0.82%) of the organs analyzed. Other than 15 min post-exposure for liver of the 0.4 mg As/kg
dose group (liver: 0.45 ± 0.37%; blood: 0.22 ± 0.04%), the similar levels of MMA(V)-derived
radioactivity between blood and liver suggested limited hepatic uptake of MMA(V).
Significant effects of time on the concentration of MMA(V)-derived radioactivity were found
in all tissues. Significant effects of dose and the interaction of dose × time on the concentration
of MMA(V)-derived radioactivity were observed in blood, liver and lung. Significant
differences in the concentration of MMA(V)-derived radioactivity were detected at several
time points in blood, liver and lung (Fig. 1).
Hughes et al. Page 5













Tissue concentration-time profiles, based on ng As/g tissue (Fig. 2), appeared parallel for both
doses of MMA(V). Comparison of the area under the curves (AUC) of MMA(V)-derived
radioactivity in blood and organs showed there was a less than a 100-fold difference between
the two administered doses (Table 1), which is suggestive of dose-dependent effects in
disposition of MMA(V).
The terminal or elimination half-lives of MMA(V)-derived radioactivity in tissues of 0.4 mg
As/kg dosed mice ranged from 4 h in liver to 15 h in kidney (Table 1). In tissues of 40 mg As/
kg dosed mice, the elimination half-lives ranged from 4 h in liver to 13 h in kidney.
MMA(V)-derived radioactivity was rapidly excreted in urine and feces after po administration
(Fig. 3). Mice administered 0.4 or 40 mg As/kg [14C]-MMA(V) excreted approximately 80%
of the radiolabel by 8 h after treatment in urine and feces. Statistical analysis of the urinary and
fecal data showed significant effects of dose and time. For urine, significantly greater excretion
of the 0.4 mg As/kg dose occurred at 0.25, 4, 8, 12 and 24 h. For feces, significantly greater
excretion of the 40 mg As/kg dose occurred at 8, 12 and 24 h.
The relative bioavailability of MMA(V)-derived radioactivity was 0.81 and 0.6 for 0.4 and 40
mg As/kg MMA(V), respectively. Clearance of MMA(V)-derived radioactivity from blood
was 50 g/h for both doses.
Speciation of urinary arsenic excreted by mice administered MMA(V) or MMA(III) showed
differences in their metabolism (Fig. 4). The metabolism of MMA(V) was minimal and that
of MMA(III) was extensive. In urine of control mice, DMA(V) (0.11 ± 0.02 μg/ml), DMA(III)
(0.180 ± 0.003 μg/ml) and TMAO (0.052 ± 0.009 μg/ml) were detected and may have originated
from the mouse diet. After accounting for background levels of urinary arsenicals, less than
10% of the excreted arsenicals for either dose of MMA(V) were in di- and trimethylarsenic
forms (Table 2). In contrast, after administration of MMA(III), more than 90% of the excreted
arsenicals were in dimethylarsenic forms. The presence of MMA(V) in urine of MMA(III)-
treated mice indicates that excreted parent had oxidized at some point in the experiment. An
unknown percentage of excreted DMA(III) may have also oxidized to DMA(V) in urine.
Speciation of tissue arsenicals showed that at 2 h post-dosing, administered MMA(V) and
MMA(III) were converted to dimethylarsenic (DMA) (Table 3). Because the digestion method
used for tissue analysis of arsenicals converts trivalent arsenic to pentavalent arsenic, results
are shown as MMA and DMA without regard to oxidation state. TMAO was not detected in
the tissues. The highest levels of methylated arsenic (MMA and DMA) at this time point were
urinary bladder for both dose groups of MMA(V) and lung of MMA(III)-dosed mice. There
was a marked contrast in the tissue distribution of methylated arsenic of MMA(V)- and MMA
(III)-dosed mice. In the former, adjusting for background levels of MMA and DMA in tissues,
the distribution of methylated arsenic in the form as DMA ranged from 0% in blood to 19%
in lung in the low dose group and from 4% in bladder to 25% in lung in the high dose group.
In MMA(III)-dosed mice, the distribution of methylated arsenic in the form as DMA ranged
from 75% in blood to 100% in bladder, kidney and lung.
The sum of concentrations of arsenic species from the HG-AAS analysis agreed with total
arsenic concentrations determined by HG-AFS relatively well as demonstrated in the recovery
results. Recovery of arsenic in urine was 104.3 ± 15.4% and 103.7 ± 12.1% for 0.4 and 40 mg
As/ kg MMA(V), respectively. Recovery of arsenic in urine for MMA(III)-treated mice was
104.8 ± 17.1%. Recovery of arsenic in tissues of MMA(III)-treated mice was 103.6 ± 33.5%
and 113.7 ± 11.7% for kidney and liver, respectively. Recovery of arsenic in kidney was 76.0
± 25.7% and 113.0 ± 20.9% for 0.4 and 40 mg As/kg MMA(V), respectively. Recovery of
arsenic in liver was 87.9 ± 23.6% for 40 mg As/kg MMA(V). Other doses or tissues were not
reported because either the tissues were used up in the speciation analysis (bladder) or the level
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of arsenic detected in the tissues (blood, liver and lung) was at or below the detection limit of
the instrument.
Discussion
Oral administration of MMA(V) to mice results in its rapid absorption, distribution and
elimination. The time to peak concentration of MMA(V)-derived radioactivity in blood (1–4
h) of mice was slightly earlier than that observed in hamsters (27 mg As/kg) (6 h), sheep (10
mg As/kg) (5 h) and goats (10 mg As/kg) (5 h) treated similarly (Shariatpanahi and Anderson,
1984; Yamauchi et al., 1988). In humans, MMA(V) (500 μg As) was also rapidly absorbed,
based on the percentage of the dose (46%) recovered in urine 4 h after oral administration
(Buchet et al., 1981). In the present study, MMA(V)-derived radioactivity was detected in all
organs analyzed 0.25 h after administration of MMA(V), which indicates that it distributed
rapidly. For both dose levels of MMA(V), 80% of the administered dose was excreted 8 h post-
exposure in urine and feces, which also indicates it was rapidly eliminated.
The gastrointestinal absorption of MMA(V) in mice appeared to be dose dependent, with
reduced fractional absorption at the higher dose level. By 24 h post-exposure, a significantly
higher percentage of the administered dose was excreted in feces by the high dose group.
During this same time frame, a significantly higher percentage of the dose was excreted in
urine by the low dose group. There was also less than a 100-fold difference in the AUC for the
tissue concentration-time profiles between the two doses of MMA(V), although there was a
100-fold difference in the dose administered. At most of the time points where a significant
difference in tissue concentration of arsenic was detected, a significantly greater concentration
was in the low dose mice.
In hamsters, Yamauchi et al. (1988) observed lower urinary excretion (<35% of the dose) of
orally administered MMA(V) (27 mg As/kg) than reported for humans (90% of 500 μg As
dose) (Buchet et al., 1981), sheep (53% of 10 mg As/kg dose) and goats (50% of 10 mg As/kg
dose) (Shariatpanahi and Anderson, 1984). After ip administration of MMA(V) (27 mg As/
kg) in hamsters, 80% of the dose was excreted in urine by 24 h, whereas fecal excretion was
1% (Yamauchi et al., 1988). In contrast, 56% of a po dose of MMA(V) (27 mg/kg) in hamsters
was excreted in feces by 24 h (Yamauchi et al., 1988). Thus, it appears that the hamster has
relatively lower oral absorption of MMA(V) than other species. The results of parenteral
administration of MMA(V) in hamsters also suggest that there is minimal biliary excretion of
MMA(V). In rats, it has been recently reported that biliary excretion of iv administered MMA
(V) (0.2–0.25 mg/kg) was low (Cui et al., 2004; Suzuki et al., 2004a). Low biliary excretion
of administered MMA(V) in the mouse may also be likely and would suggest that absorbed
MMA(V) would be preferentially excreted in urine. In mice administered MMA(V) (0.4 or 40
mg As/kg) iv, 4–9% of the dose was excreted in feces and 70–75% in urine by 24 h (Hughes
and Kenyon, 1998). Interestingly, administered iAs undergoes biliary transport in the form of
an MMA(III) thiol complex in several species, including the hamster (Gregus et al., 2000; Kala
et al., 2000) and rat (Cui et al., 2004).
The absorbed dose of MMA(V)-derived radioactivity was rapidly excreted in urine by mice.
The rapid urinary excretion accounts for the highest tissue concentrations of MMA(V)-derived
radioactivity in kidney and bladder compared to the other organs. Kidney and bladder also had
the longest tissue elimination half-lives of MMA(V)-derived radioactivity, which suggests that
the absorbed dose is continuously excreted in the urine. Our results agree with those of
Yamauchi et al. (1988) who demonstrated that in hamsters dosed po with MMA(V) (27 mg
As/kg), kidney had the highest arsenic concentration and the slowest arsenic clearance rate of
the organs analyzed. MMA(V) (500 μg As) administered to humans is also rapidly excreted,
with approximately 46% and 70% of the dose excreted in urine by 4 and 24 h post-
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administration, respectively (Buchet et al., 1981). Clearance (50 g/h) of MMA(V)-derived
radioactivity from blood of mice was the same for both administered doses. This suggests that
the urinary excretion of absorbed MMA(V) in mice after oral administration was not affected
by dose, which is in agreement with data following iv administration of similar doses of MMA
(V) in this species (Hughes and Kenyon, 1998).
The level of metabolism of MMA(V) was in sharp contrast to the metabolism of MMA(III)
after po administration. For low dose mice, no products attributed to methylation of
administered MMA(V) were detected in urine; only a small percentage (1.5%) of the excreted
dose was in the form as MMA(III). For high dose mice, approximately 10% of the excreted
dose in urine could be attributed to the methylation of administered MMA(V), as DMA(V),
DMA(III) and TMAO were detected above background levels. For MMA(III)-treated mice,
>90% of the excreted dose in urine was in the form of DMA(V) and DMA(III), which resulted
from methylation of administered MMA(III). In tissues of MMA(V)-treated mice, 25% or less
of the total methylated arsenic species (MMA + DMA) were due to methylation of administered
MMA(V). In tissues of MMA(III)-treated mice, 75–100% of the methylated arsenic species
were due to methylation of administered MMA(III). Minimal metabolism of MMA(V), as
measured by urinary metabolites, was also reported by our laboratory after iv administration
of MMA(V) at the same dose levels and in the same strain of mice (Hughes and Kenyon,
1998). Yamauchi et al. (1988) reported similar observations in the hamster after po
administration of MMA(V) (27 mg As/kg). Approximately 5% of the excreted dose was in the
form as DMA and <1% in the form as TMAO. Similarly low levels of DMA were also found
in tissues of MMA(V)-treated hamsters (Yamauchi et al., 1988). In rats, MMA(V) is excreted
in urine primarily intact after iv administration (0.2–0.25 mg/kg) (Cui et al., 2004; Suzuki et
al., 2004a). In humans, metabolism of orally administered MMA(V) (500 μg As) to DMA is
also low; approximately 13% of the excreted dose of administered MMA(V) was in the form
as DMA (Buchet et al., 1981).
Regarding the detection of DMA(III) in urine, it has recently been reported that DMA(III) has
been mistaken for a sulfur-containing dimethylarsenic compound (Hansen et al., 2004; Suzuki
et al., 2004a, 2004b). These results were based on mass spectral analysis of several products
formed from DMA(V) by reacting it directly with sulfur-containing compounds under acidic
conditions. This metabolite was detected in urine of sheep fed seaweed, which contains
arsenosugars (Hansen et al., 2004). Suzuki et al. (2004a, 2004b) have also detected sulfur-
containing dimethylarsenic compounds in liver of rats administered iv DMA(V) (0.5 mg As/
kg) or thiol complexes of trivalent monomethyl- or dimethylarsenic (0.5 mg As/kg). The
trivalent dimethylarsenic standard we used was dimethylarsine iodide, which forms DMA(III)
when dissolved in water. Whether or not the trivalent dimethylarsenic species we detected in
urine was DMA(III) or the sulfur-containing dimethylarsenic compound is not known and
requires additional studies for verification.
The in vivo MMA(V) and MMA(III) metabolism results of this study and those of others with
MMA(V) (Buchet et al., 1981; Cui et al., 2004; Suzuki et al., 2004a, 2004b; Yamauchi et al.,
1988) parallel the results from in vitro metabolism studies with these two organic arsenicals
(Styblo et al., 1995, 2000). In the in vivo and in vitro studies, metabolism of MMA(V) was
minimal, but it was extensive for MMA(III). In studies with rat liver cytosol, MMA(III) was
quantitatively metabolized to DMA. More than 95% of MMA(III) added to the cytosolic
incubate was methylated to DMA, whereas only 3% of MMA(V) was similarly converted
(Styblo et al., 1995). In rat hepatocytes, approximately 90% of MMA(III) (1 μM), but only 5%
of MMA(V) (1 μM) was methylated to DMA (Styblo et al., 2000).
There are three potential factors that may limit the in vivo methylation of MMA(V). These
may include uptake of MMA(V) into the liver, reduction of MMA(V) and its rapid distribution
Hughes et al. Page 8













to the kidney for elimination. MMA(V) does not appear to be taken up well by the liver, a
major site of iAs metabolism (Thomas et al., 2001; Vahter and Concha, 2001). The AUC from
the liver concentration-time profiles of MMA(V)-treated mice were only slightly greater (1.1-
to 1.4-fold) than the blood AUC, suggesting limited hepatic uptake of MMA(V). Yamauchi et
al. (1988) have reported that the concentration of mono- and dimethylarsenic was lower in liver
than in blood of hamsters administered MMA(V) (27 mg As/kg) po. If MMA(V) is not taken
up into the liver, its methylation is likely to be limited. On the other hand, MMA(III) appears
to be more readily taken up than MMA(V) by the liver. In the present study, hepatic levels of
DMA were higher in MMA(III)-treated mice (212 ng As/g) than in MMA(V)-treated mice (12
ng As/kg) at a similar administered dose (0.4 mg As/kg) 2 h post-dosing. This suggests that
MMA(III), but not MMA(V), was readily taken up by the liver and methylated. Uptake of
MMA(III) (1 μM) by rat hepatocytes was approximately 50% of the total arsenic, while uptake
of MMA(V) (1 μM) was considerably lower (Styblo et al., 2000). Uptake of MMA(III) was
also greater than that of MMA(V) by Chinese hamster ovary cells (Dopp et al., 2004). The
reason for this difference in hepatic uptake of these two arsenicals is not known. Arsenate
(pentavalent iAs), because it is an analogue of phosphate (Dixon, 1997), is transported across
membranes by phosphate carriers (Huang and Lee, 1996; Kenney and Kaplan, 1988). However,
MMA(V) is not a phosphate analogue (Delnomdedieu et al., 1995), and thus it is unlikely to
be transported into cells by phosphate carriers. MMA(V) has a pKa1 of 2.6 (Braman et al.,
1977), and would be expected to be ionized at physiological pH, thus decreasing its ability to
diffuse passively across membranes. Arsenite (trivalent iAs) is transported across membranes
by aquaglyceroporins and hexose permeases (Liu et al., 2002, 2004a, 2004b). Whether or not
MMA(III) is transported by these mechanisms is not known. What is known is that hepatic
uptake of MMA(III) is greater than that of MMA(V), which most likely impacts the extent of
their methylation.
According to Challenger (1945), reduction of pentavalent arsenic to a trivalent state is required
before methylation can occur. In the present study, less than 12% of the excreted arsenic was
in a form that resulted from the initial reduction of administered MMA(V). A mechanism to
reduce MMA(V) may not be readily available so that it can be methylated. An MMA(V)
reductase has been partially purified from rabbit (Zakharyan and Aposhian, 1999) and human
liver (Zakharyan et al., 2001). This enzyme appears to be a member of the glutathione-S-
transferase omega (GST-O) family (Zakharyan et al., 2001). Based on immunohistochemical
studies, this enzyme has been detected in a number of mammalian species and is widely
distributed in a number of tissues (Board et al., 2000; Yin et al., 2001). In vitro studies indicate
that this enzyme has a relatively high KM for MMA(V) (Zakharyan and Aposhian, 1999). The
capability of GST-O in reducing MMA(V) in vivo is unknown. Another possibility is that
MMA(V) is not an intermediate in the pathway for iAs metabolism as proposed by Hayakawa
et al. (in press). MMA(III) is already in the trivalent state, so it can be directly methylated to
form DMA(V) as proposed by Challenger (1945). Complexation of MMA(III) with glutathione
before methylation would be required by the Hayakawa et al. (in press) pathway. Regardless
of the mechanism, quantitative formation of DMA from MMA(III) was observed in vivo in
the present study and in vitro by Styblo et al. (1995, 2000).
A major portion of the MMA(V) absorbed into the blood from the gut was rapidly transported
to the kidneys and eliminated in urine. This has been observed in mice (Hughes and Kenyon,
1998) and rats (Cui et al., 2004; Suzuki et al., 2004a) after iv administration of MMA(V). If
an arsenical is rapidly eliminated from the body, the likelihood of it being methylated is greatly
minimized. All of these potential processes, the low hepatic uptake of MMA(V), the low MMA
(V) reducing ability within the hepatocyte and the rapid distribution of MMA(V) to kidney and
bladder followed by its elimination in urine may explain the low methylation of MMA(V) to
di- and trimethylated arsenic species.
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In summary, MMA(V) is rapidly absorbed, distributed and eliminated in urine after oral
administration in the mouse. The route of excretion of administered MMA(V) was dose
dependent, with greater urinary excretion in the low dose group and greater fecal excretion in
the high dose group. This and other evidence suggests oral absorption of MMA(V) was dose
dependent. Methylation of MMA(V) was minimal and that of MMA(III) was extensive.
Arsenic in tissues and urine of MMA(V)-dosed mice was primarily in the form as
monomethylarsenic. In contrast, arsenic in tissues of MMA(III)-dosed mice was primarily in
the form as dimethylarsenic and that in urine was predominantly di-and trimethylarsenic.
Administered dose of MMA(V) did not appear to inhibit its metabolism, as di- and
trimethylarsenic were detected in urine of the high dose group, but not in urine of the low dose
group. The low methylation and rapid excretion of MMA(V) may partly explain its relatively
low toxicity in mammals.
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Concentration of MMA(V)-derived radioactivity, based on percentage of dose/g, in tissues of
mice over time after po administration of 0.4 (■) or 40 (○) mg As/kg [14C]-MMA(V). The data
represent mean ± SD, N = 4, except for bladder, 0.4 mg As/kg dose, at 15 min, where N = 3.
Significant dose effects (P < 0.05) on the concentration of MMA(V)-derived radioactivity in
tissues were observed; *significantly greater than 40 mg As/kg; † significantly greater than 0.4
mg As/kg.
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Concentration of arsenic, based on ng As/g, in tissues of mice over time after po administration
of 0.4 (■) or 40 (○) mg As/kg [14C]-MMA(V). The data represent mean ± SD, N = 4, except
for bladder, 0.4 mg As/kg dose, at 15 min, where N = 3.
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Time course of the excretion of MMA(V)-derived radioactivity in urine and feces of mice after
po administration of 0.4 (■) or 40 (○) mg As/ kg [14C]-MMA(V). The data represent mean ±
SD, N = 4. Significant dose effects (P < 0.05) on the cumulative percent dose of MMA(V)-
derived radioactivity excreted in urine and feces were observed. *Significantly greater than 40
mg As/kg; *significantly greater than 0.4 mg As/kg.
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Concentration (μg/ml) of speciated arsenicals excreted in cumulative 24-h urine of mice
administered po 0.4 or 40 mg As/kg MMA(V) or 0.4 mg As/kg MMA(III). Control animals
were administered water. Aliquots of urine were directly analyzed by pH selective HG-AAS.
The data represent mean ± SD, N = 3 for MMA(V)-treated mice and N = 4 for control and
MMA(III)-treated mice.
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